Cargando…
Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of cancer patients on active treatment receiving mRNA-based SARS-CoV-2 vaccine by detection of anti-SARS-CoV-2 S1 IgG antibodies in serum, before, a...
Autores principales: | Janzic, Urska, Bidovec-Stojkovic, Urska, Mohorcic, Katja, Mrak, Loredana, Dovnik, Nina Fokter, Ivanovic, Marija, Ravnik, Maja, Caks, Marina, Skof, Erik, Debeljak, Jerneja, Korosec, Peter, Rijavec, Matija |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245563/ https://www.ncbi.nlm.nih.gov/pubmed/35678621 http://dx.doi.org/10.2217/fon-2022-0148 |
Ejemplares similares
-
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
por: Janzic, Urska, et al.
Publicado: (2023) -
188P Efficacy of SARS-CoV-2 based mRNA vaccines for patients with thoracic malignancies with 6 months follow up: A prospective observational study
por: Janzic, U., et al.
Publicado: (2022) -
Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients
por: Šokić, Maruša Kopač, et al.
Publicado: (2022) -
Chemokines during anaphylaxis: the importance of CCL2 and CCL2-dependent chemotactic activity for basophils
por: Vantur, Romana, et al.
Publicado: (2020) -
Fatal Hymenoptera Venom–Triggered Anaphylaxis in Patients with Unrecognized Clonal Mast Cell Disorder—Is Mastocytosis to Blame?
por: Rijavec, Matija, et al.
Publicado: (2023)